Biomedicum Helsinki
Helsinki, 00029, Finland
NCT Number: NCT01315964
Plant stanol esters as part of daily diet can decrease serum level of LDL-cholesterol up to 10%. This decrease diminishes the risk of development of premature atherosclerosis and it´s complications (e.g., acute myocardial infarction) in adult human subjects.
The purpose of the present study is to evaluate among healthy human subjects (N=100) effects of plant stanol esters (3 grams/day for 6 months) as part of daily diet in margarine on arterial endothelial cells, arterial stiffness, autonomic innervation of the arteries, arterial blood flow and serum fats. The non-invasive arterial measurements (VaSera®, EndoPat® and WinCRPS®) are performed and blood samples are taken at the beginning and at the end of the 6-month-long study period. Also questionnaires concerning healthy, and life and dietary habits are fulfilled. Dietary records (twice for a 3-day-period) are done.
Hypothesis of the study is that a dietary serum cholesterol lowering intervention has beneficial influence on the early prognostic markers of premature atherosclerosis.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Helsinki, 00029, Finland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
Other names: Benecol
Time frame: 6 months
Time frame: 6 months
University of Helsinki
Other
Effects of Dietary Plant Stanol Esters of Blood Flow Among Healthy Adult Human Subject. The BLOOD FLOW -Study
Acronym: BLOOD FLOW
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05906797
Arterial Occlusive Diseases, Arteriosclerosis
Catania, Italy
View Trial DetailsNCT02991703
Arterial Occlusive Diseases, Arteriosclerosis
Nantes, France
View Trial DetailsNCT04167761
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT02505399
Arterial Occlusive Diseases, Arteriosclerosis
Toulouse, Haute-Garonne, France
View Trial Details